Methods of treating cachexia

Details Methods of treating cachexia Methods of treating cachexia

1999-10-15

2008-08-26

Rao, Manjunath (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S175000

Reexamination Certificate

active

07417038

ABSTRACT:
A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the 10 method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a 13 receptor blocker; an imidazoline receptor antagonist; a centrally acting tx receptor antagonist; a peripherally acting ct receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduce SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.

REFERENCES:
patent: 0 714 663 (1996-06-01), None
patent: 09 071 586 (1997-03-01), None
patent: WO 96/24373 (1996-08-01), None
patent: WO 98/15267 (1998-04-01), None
patent: WO 99/02142 (1999-01-01), None
The RALES Investigators. Effectiveness of Spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. American Journal Cardiology, vol. 78, pp. 902-907, 1996.
Freeman et al. Nutrition Reviews, Oct. 1994. vol. 52, No. 10, pp. 340-347.
Packer et al, New England Journal of Medicine, 1996. vol. 334, pp. 1349-1355.
Coats, et al., “Prevention and reversal of cardiac cachexia in patients with severe heart failure by carvedilol: Results of the Copernicus study” Scientific Sessions 2001 of the American Heart Association Supplement 104(17): II-437 (2001).
Saitoh, et al., “Carteolol improves body weight and visceral fat weight gains in OLETF rates, a model of NIDDM with mild obesity”Diabetologia, 16thInternational Diabetes Federation Congress; Helsinki, Finland, Supplement 1, 40(1): A365 (1997).
Anker & Coats, “Cardiac Cachexia. A syndrome with impaired survival and immune and neuroendocrine activation,”Chest115:836-847 (1999).
Anker & Rauchhaus, “Insights into the pathogenesis of chronic heart failure: immune activation and cachexia,”Curr Opin Cardiol14(3):211-216 (1999).
Anker, “Catecholamine levels and treatment in chronic heart failure,”Eur. Heart J.19(Suppl F.):56-61 (1998).
Anker, “Relation between serum urice acid and lower limb blood flow in patients with chronic heart failure,”Heart78:39-43 (1997).
Anker, et al., “Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure,”European Heart Journal20:683-693 (1999).
Anker, et al., “Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia,”Circulation96:526-534 (1998).
Anker, et al., “Loss of bone mineral in patients with cachexia due to chronic heart failure,”Am J Cardiol83:612-615 (1999).
Anker, et al., “The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure,”European Heart Journal18:259-269 (1997).
Anker, et al., “Tumor necrosis factor and steroid metabolism in chronic heart failure: Possible relation to muscle wasting,”J Amer Coll Cardiol30:997-1001 (1997).
Anker, et al., “Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure,”Q. J. Med.91:199-203 (1998).
Benedict & Grahame-Smith, “Plasma adrenaline and noradrenaline concentrations and dopamine-b-hydroxylase activity in myocardial infarction with and without cardiogenic shock,”British Heart Journal42:214-220 (1979).
Berne, “Effect of epinephrine and norepinephrine on coronary circulation,”Circ Res6:644-655 (1958).
Besarb, et al., “The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epotein,”N Eng J Med339(9):584-590 (1998).
Brink, et al., “Angiotension II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism,”J Clin Invest97(11):2509-2516 (1996).
Chilain, et al., “Andrenergic coronary tone during submaximal exercise in the dog is produced by circulating catecholamines,”Cir Res58:68-62 (1986).
Chua, et al., “Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure,”J Am Coll Cardiol27:650-657 (1996).
Coats, “Symptoms and quality of life In heart failure: the muscle hypothesis,” “Symptoms and quality of lifein heart failure: the muscle hypothesis,”Br. Heart J72:S36-S39 (1994).
Cowie, et al., “The epidemiology of heart failure,”European Heart Journal18:205-225 (1997).
Daneryd, et al., “Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study,”Cancer Res.58(23):5374-5379 (1998).
Davenport, “Characterization of [125I]-PD164333, an ETAselective non-peptide radiolabelled antagonists, in normal and diseased human tissues,”Br. J Pharmacol123(2):223-30 (1998).
Doherty, et al., “In vitro and in vivo studies with a series of hexapeptide endothelin antagonists,”J Cardiovascular Pharmacology22(Suppl 8):S98-S102 (1993).
D'Uscio, et al., “Efects of chronic ETA-receptor blockade in angiotension II-induced hnypertension,”Hypertension29(1 Pt. 2):435-41 (1997).
Francis, “Camparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure,”Circulation82:1724-1729 (1990).
Gagnon & Bruera, “A review of the dug treatment of cachexia associated with cancer,”Drugs55(5):675-688 (1998).
Goldstein, “Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology,”Am J Cardiol48:1147-54 (1981).
Gorter, “Management of anorexia-cachexia associated with cancer and HIV infection,”Oncology5(9):13-17 (1991).
Greenbaum, et al., “Host cathepsin D response to tumor in the normal and pepstatin-treated mouse,”Cancer Res.43(6):2584-2587 (1983).
Harris,“Congestive cardiac failure: central role of the arterial blood pressure,”Br Heart J58:190-203 (1987).
Hashida, “Inhibitions by E-64 derivatives of rat liver cathespsin B and cathespsin L in vitro and in vivo,”J Biochem88:1805-1811 (1980).
Heusch & Deussen, “The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog,”Circ Res53:8-15 (1983).
Heusch, “α-Adrenergic mechanisms in mycocardial Ischemia,”Circulation81:1-13 (1990).
Huang, et al., “Antialdosterone therapy in severe chronic congestive heart failure,”Zhonghua Xinxueguanbing Zazhi24(1):12-15 (1996).
Ihara, et al., “In vitro biological profile of a highly potent novel endolethial (ET) antagonist BQ-123 selective for the ETAreceptor,”J Cardiovasc Pharmcol20(Suppl. 12):S11-S14 (1992).
Ishikawa, et al., “Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788,”Proc Natl Acad Sci USA91:4892-4892 (1994).
Jae, et al., “Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETBmixed antagonists,”J Med Chem40:3217-3227 (1997).
Kalimi, et al., “Effects of antimineralocorticoid RU 26752 on steroid-induced hypertension in rats,”Am J Phusiol258(5, Pt 1):E737-9 (1990).
Kichuk, et al., “Angiotension-converting enzyme inhibitors promote nitric oxide production in coronary m

Affiliated with

Also associated with

Rating

Methods of treating cachexia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating cachexia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cachexia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4000058